Xospata for adult patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Xospata ( Gilteritinib ) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia ( AML ) with a FLT3 mutation as detected by an FDA-approved test.
The FDA has also approved an expanded indication for a companion diagnostic, to include use with Xospata.
The LeukoStrat CDx FLT3 Mutation Assay is used to detect the FLT3 mutation in patients with acute myeloid leukemia.
Approximately 25 to 30% of patients with acute myeloid leukemia have a mutation in the FLT3 gene.
These mutations are associated with a particularly aggressive form of the disease and a higher risk of relapse.
Xospata targets this gene and is the first drug to be approved that can be used alone in treating patients with acute myeloid leukemia having a FLT3 mutation who have relapsed or who don’t respond to initial treatment.
Acute myeloid leukemia is a rapidly progressing cancer that crowds out normal cells in the bone marrow and bloodstream, resulting in low numbers of normal blood cells and a continuous need for transfusions.
The National Cancer Institute ( NCI ) estimates that approximately 19,520 people will be diagnosed with acute myeloid leukemia this year; approximately 10,670 patients with acute myeloid leukemia will die of the disease in 2018.
The efficiency of Xospata was studied in a clinical trial of 138 patients with relapsed or refractory acute myeloid leukemia having a confirmed FLT3 mutation.
Twenty-one percent of patients has achieved complete remission ( no evidence of disease and full recovery of blood counts ) or complete remission with partial hematologic recovery ( no evidence of disease and partial recovery of blood counts ) with treatment.
Of the 106 patients who required red blood cell or platelet transfusions at the start of treatment with Xospata, 31% became transfusion-free for at least 56 days.
Common side effects reported by patients in clinical trials were muscle and joint pain ( myalgia / arthralgia ), fatigue and elevated liver enzymes ( liver transaminase ).
Health care providers are advised to monitor patients for posterior reversible encephalopathy syndrome ( a syndrome characterized by headache, confusion, seizures and visual loss ), prolonged QT interval ( a heart rhythm condition that can potentially cause fast, chaotic heartbeats ) and pancreatitis ( inflammation in the pancreas ).
Rare cases of differentiation syndrome ( symptoms of which may include fever, cough, trouble breathing, fluid around the lungs or heart, rapid weight gain, swelling, and renal or hepatic dysfunction ) have been seen in patients taking Xospata.
Women who are pregnant or breastfeeding should not take Xospata because it may cause harm to a developing fetus or newborn baby. ( Xagena )
Source: FDA, 2018
COVID-19 can have fatal consequences for people with underlying cardiovascular disease and cause cardiac injury even in patients without underlying...
FDA: Opdivo plus Yervoy as first-line treatment of patients with metastatic non-small cell lung cancer with PD-L1 expression greater than or equal to 1%
Opdivo ( Nivolumab ) 3 mg/kg plus Yervoy ( Ipilimumab ) 1 mg/kg ( injections for intravenous use ) was...
The FDA ( U.S. Food and Drug Administration ) has approved Reyvow ( Lasmiditan ) tablets for the acute treatment...
Tthe FDA ( U.S. Food and Drug Administration ) has approved Reyvow ( Lasmiditan ) an oral medication for the...
Praluent to prevent myocardial infarction, stroke and unstable angina requiring hospitalization, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...
The results from the phase 3 ADMIRAL clinical trial comparing Gilteritinib ( Xospata ) to salvage chemotherapy in adult patients...
The European Commission has approved a label update for the use of once-daily Relvar Ellipta ( Fluticasone furoate / Vilanterol,...
Acute myeloid leukemia ( AML ) remains a highly resistant disease to conventional chemotherapy, with a median survival of only...
CAR-T cell therapy, Kymriah for B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma: approved in European Union
The European Commission ( EC ) has approved Kymriah ( Tisagenlecleucel, formerly CTL019 ). The approved indications are for the...
FDA has approved Tibsovo, the first targeted treatment, for patients with relapsed or refractory acute myeloid leukemia with mutations in the IDH1 gene
The FDA ( U.S. Food and Drug Administration ) has approved Tibsovo ( Ivosidenib ) tablets for the treatment of...